ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Subclinical Borderline Rejection: More Than Meets the Eye?

M. Bernard, G. Agarwal, H. Fatima, B. Julian, C. Kew, V. Kumar, S. Mehta, S. Ong, A. Patel, G. Towns, M. Seifert, R. Mannon.

UAB School of Medicine, Birmingham.

Meeting: 2018 American Transplant Congress

Abstract number: D189

Keywords: Graft survival, Kidney transplantation, Outcome, Protocol biopsy

Session Information

Session Name: Poster Session D: Kidney: Acute Cellular Rejection

Session Type: Poster Session

Date: Tuesday, June 5, 2018

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Purpose: Surveillance biopsies can detect subclinical T cell mediated rejection (SC-TCMR) or subclinical borderline rejection (SC-B-TCMR) in patients with normal/stable creatinine, but the impact on long-term outcomes is unclear, particularly in centers enriched for high immune risk populations such as black recipients. We hypothesized that SC-B-TCMR, which is frequently not treated, will behave similarly as SC-TCMR with worse outcomes than those with no major surveillance abnormality (NOMOA).

Methods: We reviewed all kidney transplant biopsies (N=601) performed at our center from May 2015 to December 2016, immediately following inception of 6-month surveillance biopsies in post-transplant management. The primary exposure was SC-B-TCMR or SC-TCMR by Banff 2013 criteria. The primary outcome was a composite endpoint of acute rejection after surveillance and death-censored graft loss.

Results: We identified 166 (28%) biopsies performed for 6-month surveillance. Our cohort was 55% black and 61% were recipients of deceased donor kidneys. We detected SC-B-TCMR in 48 (29%) and SC-TCMR in 9 (5%) of recipients. All SC-TCMR and 42% of SC-B-TCMR were treated with increased immunosuppression, while 58% of SC-B-TCMR were managed expectantly. The composite endpoint occurred in 10/166 (6%) overall, including 15% of SC-B-TCMR and 20% of SC-TCMR versus only 1% of NOMOA (P<0.001). In SC-B-TCMR, the composite endpoint occurred in 10% that were treated with increased maintenance or pulse corticosteroid therapy (clinician's discretion) compared to 18% in those expectantly managed (P=0.001 compared to NOMOA). Despite similar SC-B-TCMR rates by race, black recipients with SC-B-TCMR had worse outcomes compared to non-black SC-B-TCMR and all-race NOMOA (P<0.0001, Figure).

Conclusions: SC-B-TCMR and SC-TCMR were detected in 34% of recipients and had similar outcomes that were worse than for those with NOMOA. Black recipients had the worst outcomes after SC-B-TCMR. The impact of treating subclinical borderline rejection must be validated in prospective studies to personalize immunosuppression in high-risk populations.

CITATION INFORMATION: Bernard M., Agarwal G., Fatima H., Julian B., Kew C., Kumar V., Mehta S., Ong S., Patel A., Towns G., Seifert M., Mannon R. Subclinical Borderline Rejection: More Than Meets the Eye? Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Bernard M, Agarwal G, Fatima H, Julian B, Kew C, Kumar V, Mehta S, Ong S, Patel A, Towns G, Seifert M, Mannon R. Subclinical Borderline Rejection: More Than Meets the Eye? [abstract]. https://atcmeetingabstracts.com/abstract/subclinical-borderline-rejection-more-than-meets-the-eye/. Accessed May 25, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences